Contemporary Issues in Lung CancerJones & Bartlett Publishers, 2009 M02 12 - 364 pages In the United States, lung cancer is the second most commonly diagnosed cancer and the leading cause of cancer death. Even more devastating is its five-year survival rate of only 15.8%. Despite these dismal facts, lung cancer receives little national attention and research and funding for lung cancer lags behind other cancers. The intent of Contemporary Issues in Lung Cancer: A Nursing Perspective Second Edition is to provide oncology nurses and healthcare professionals with in-depth information on the issues that surround this disease, so that they might impact both education and research and provide better care for their patients. |
From inside the book
Results 1-5 of 32
Page 6
... carcinoma, and large cell carcinoma. Table 1–2 Source: SEER, data 2001–2005. Adenocarcinoma represents about 40% of lung cancer cases in the 6 Chapter 1: Separating Out the Differences Between Lung Cancers. Age Percentage at Diagnosis ...
... carcinoma, and large cell carcinoma. Table 1–2 Source: SEER, data 2001–2005. Adenocarcinoma represents about 40% of lung cancer cases in the 6 Chapter 1: Separating Out the Differences Between Lung Cancers. Age Percentage at Diagnosis ...
Page 7
... carcinoma and added a new category of large cell neuroendocrine carcinoma (Travis et al., 1999; Junker, Wiethege, & Muller, 2000). This new category divides cell types into: classical small cell lung (SCLC), large cell neuroendocrine ...
... carcinoma and added a new category of large cell neuroendocrine carcinoma (Travis et al., 1999; Junker, Wiethege, & Muller, 2000). This new category divides cell types into: classical small cell lung (SCLC), large cell neuroendocrine ...
Page 9
... Carcinoma in situ. T1 Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in main bronchus). T2 Tumor with any of ...
... Carcinoma in situ. T1 Tumor 3 cm or less in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in main bronchus). T2 Tumor with any of ...
Page 10
... Carcinoma TX N0 M0 Stage 0 Tis N0 M0 Stage IA T1 N0 M0 Stage IB T2 N0 M0 Stage IIA T1 N1 M0 Stage IIB T2 N1 M0 T3 N0 M0 Stage IIIA T1 N2 M0 T2 N2 M0 T3 N1 M0 T3 N2 M0 Stage IIIB Any T N3 M0 T4 Any N M0 Stage IV Any T Any N M1 MYC ...
... Carcinoma TX N0 M0 Stage 0 Tis N0 M0 Stage IA T1 N0 M0 Stage IB T2 N0 M0 Stage IIA T1 N1 M0 Stage IIB T2 N1 M0 T3 N0 M0 Stage IIIA T1 N2 M0 T2 N2 M0 T3 N1 M0 T3 N2 M0 Stage IIIB Any T N3 M0 T4 Any N M0 Stage IV Any T Any N M1 MYC ...
Page 11
... Carcinoma in situ • T1: Tumor that is 3 cm in its greatest dimension, does not invade the visceral pleura, and is without bronchoscopic evidence of invasion more proximal than a lobar bronchus T1a: Tumor is 2 cm in its greatest ...
... Carcinoma in situ • T1: Tumor that is 3 cm in its greatest dimension, does not invade the visceral pleura, and is without bronchoscopic evidence of invasion more proximal than a lobar bronchus T1a: Tumor is 2 cm in its greatest ...
Contents
Oncology Treatment Modalities | 45 |
Special Issues Facing Individuals with Lung Cancer | 117 |
Psychosocial Issues of Individuals with Lung Cancer | 231 |
Assistance and Resources for Individuals Facing Lung Cancer | 255 |
Media and Future Research Directions | 301 |
Index | 353 |
Other editions - View all
Common terms and phrases
adjuvant agents aprepitant associated bevacizumab breathing breathlessness Bruera carboplatin carcinoma cell lung cancer chemotherapy chronic cisplatin Clinical Oncology clinical trials combination diagnosis disease docetaxel dose drug dyspnea EGFR erlotinib etoposide evaluation evidence-based factors fatigue gefitinib gemcitabine gene improve increased individuals indoor radon Internet intervention irinotecan Journal of Clinical lung cancer patients Medicine ment metastatic months NCCN nicotine non-small cell lung NSCLC Nursing Forum Oncology Nursing Oncology Nursing Forum paclitaxel palliative palliative care patient navigation patients and families patients with lung pemetrexed phase postoperative potential pulmonary quit smoking radiation therapy radiotherapy radon randomized receptors regimen reported resection respiratory response rate risk role SCLC score screening Sekido side effects small cell lung smoking cessation stage strategies support group surgical survival rate Symptom Management Table tients tion tobacco topotecan toxicity treat treatment tumor versus vinorelbine weight loss